BRPI0509191A - polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno - Google Patents
polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifenoInfo
- Publication number
- BRPI0509191A BRPI0509191A BRPI0509191-8A BRPI0509191A BRPI0509191A BR PI0509191 A BRPI0509191 A BR PI0509191A BR PI0509191 A BRPI0509191 A BR PI0509191A BR PI0509191 A BRPI0509191 A BR PI0509191A
- Authority
- BR
- Brazil
- Prior art keywords
- mammal
- crystalline polymorph
- bazedoxifene acetate
- estrogen
- disease
- Prior art date
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- OMZAMQFQZMUNTP-UHFFFAOYSA-N acetic acid;1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol Chemical compound CC(O)=O.C=1C=C(OCCN2CCCCCC2)C=CC=1CN1C2=CC=C(O)C=C2C(C)=C1C1=CC=C(O)C=C1 OMZAMQFQZMUNTP-UHFFFAOYSA-N 0.000 title abstract 3
- 229960003713 bazedoxifene acetate Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010065687 Bone loss Diseases 0.000 title abstract 2
- 235000012000 cholesterol Nutrition 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 229940011871 estrogen Drugs 0.000 title abstract 2
- 239000000262 estrogen Substances 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000011580 syndromic disease Diseases 0.000 title abstract 2
- 230000001457 vasomotor Effects 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title 4
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 206010030247 Oestrogen deficiency Diseases 0.000 title 1
- 230000002159 abnormal effect Effects 0.000 title 1
- 230000002357 endometrial effect Effects 0.000 title 1
- 201000006564 estrogen excess Diseases 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000035755 proliferation Effects 0.000 title 1
- 210000001519 tissue Anatomy 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 abstract 1
- 230000007123 defense Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Indole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56058204P | 2004-04-07 | 2004-04-07 | |
| US66017805P | 2005-03-10 | 2005-03-10 | |
| PCT/US2005/011724 WO2005100316A1 (en) | 2004-04-07 | 2005-04-06 | Crystalline polymorph of a bazedoxifene acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0509191A true BRPI0509191A (pt) | 2007-09-25 |
Family
ID=34966308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0509191-8A BRPI0509191A (pt) | 2004-04-07 | 2005-04-06 | polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7683051B2 (enExample) |
| EP (1) | EP1732890A1 (enExample) |
| JP (2) | JP2007532560A (enExample) |
| KR (1) | KR20060135866A (enExample) |
| AR (1) | AR048527A1 (enExample) |
| AU (1) | AU2005233133A1 (enExample) |
| BR (1) | BRPI0509191A (enExample) |
| CA (1) | CA2561010A1 (enExample) |
| CR (1) | CR8615A (enExample) |
| EC (1) | ECSP066911A (enExample) |
| IL (1) | IL178236A0 (enExample) |
| NO (1) | NO20065052L (enExample) |
| PA (1) | PA8629101A1 (enExample) |
| PE (1) | PE20060676A1 (enExample) |
| RU (1) | RU2006132180A (enExample) |
| SG (1) | SG151331A1 (enExample) |
| TW (1) | TWI346105B (enExample) |
| WO (1) | WO2005100316A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1732890A1 (en) | 2004-04-07 | 2006-12-20 | Wyeth | Crystalline polymorph of a bazedoxifene acetate |
| BRPI0509257A (pt) | 2004-04-07 | 2007-09-11 | Wyeth Corp | polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo |
| US10645562B2 (en) | 2004-09-21 | 2020-05-05 | Agis Software Development Llc | Method to provide ad hoc and password protected digital and voice networks |
| US8538393B1 (en) | 2004-09-21 | 2013-09-17 | Advanced Ground Information Systems, Inc. | Method to provide ad hoc and password protected digital and voice networks |
| AU2006263638A1 (en) * | 2005-06-29 | 2007-01-04 | Wyeth | Formulations of conjugated estrogens and bazedoxifene |
| AU2006283121A1 (en) | 2005-08-24 | 2007-03-01 | Wyeth | Bazedoxifene acetate formulations and manufacturing process thereof |
| PE20090100A1 (es) * | 2007-03-30 | 2009-02-26 | Wyeth Corp | Metodos de separacion y deteccion de acetato de bacedoxifeno en composiciones farmaceuticas |
| CZ302358B6 (cs) | 2007-07-25 | 2011-03-30 | Zentiva, A. S. | Nové soli bazedoxifenu |
| WO2009102771A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth | Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate |
| CA2714494A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth Llc | Methods of preparing polymorphic form a of bazedoxifene acetate |
| WO2009102778A1 (en) * | 2008-02-11 | 2009-08-20 | Wyeth | Amorphous polymorph of bazedoxifene acetate |
| ITMI20091109A1 (it) * | 2009-06-23 | 2010-12-24 | Wyeth Corp | Forma polimorfa d di bazedoxifene acetato e metodi per la sua preparazione |
| CA2775599A1 (en) | 2009-10-27 | 2011-05-12 | Wyeth Llc | Bazedoxifene formulations with antioxidants |
| US8154175B2 (en) * | 2009-12-16 | 2012-04-10 | Hamilton Sundstrand Corporation | Sensing device |
| WO2012007453A1 (en) | 2010-07-14 | 2012-01-19 | Sandoz Ag | Crystalline compound of 1-[4-(2-azepan-1-ylethoxy)benzyl]-2-(4-hydroxyphenyl)-3-methyl-1h-indol-5-ol |
| EP2407467A1 (de) | 2010-07-14 | 2012-01-18 | Sandoz Ag | Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure |
| WO2012037187A2 (en) * | 2010-09-14 | 2012-03-22 | Dr. Reddy's Laboratories Ltd. | Preparation of crystalline bazedoxifene and its salts |
| EP2471770A1 (en) | 2010-12-28 | 2012-07-04 | Sandoz Ag | Method of preparing polymorphic pure form A of bazedoxifene acetate |
| WO2013182170A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Enhancement of dissolution rate from pharmaceutical composition comprising bazedoxifene acetate |
| WO2013182169A1 (en) | 2012-06-07 | 2013-12-12 | Zentiva, K. S. | Process of preparation of an antioxidant-free polymorphically and chemically stable formulation of bazedoxifene acetate |
| US9751835B2 (en) | 2013-05-15 | 2017-09-05 | Indiana University Research And Technology Corporation | Processes and intermediates for preparing indole pharmaceuticals |
| CN111060619B (zh) * | 2019-12-18 | 2022-11-18 | 北京鑫开元医药科技有限公司 | 一种醋酸巴多昔芬杂质的检测方法 |
| US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780497A (en) | 1996-04-19 | 1998-07-14 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| SK281737B6 (sk) | 1996-04-19 | 2001-07-10 | American Home Products Corporation | 2-fenylindolové zlúčeniny, farmaceutický prostriedok s ich obsahom a ich použitie |
| US5880137A (en) | 1996-04-19 | 1999-03-09 | American Home Products Corporation | 2-phenyl-1- 4-(amino-1-yl-alk-1-ynyl)-benzyl!-1H-indol-5-ols as estrogenic agents |
| US5998402A (en) | 1996-04-19 | 1999-12-07 | American Home Products Corporation | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents |
| TW397821B (en) | 1996-04-19 | 2000-07-11 | American Home Produits Corp | 3-[4-(2-phenyl-indole-1-ylmethyl)-phenyl]-acrylamides and 2-phenyl-1-[4-(amino-1-yl-alk-1-ynyl)-benzyl]-1H-indol-5-ol as well as pharmaceutical compositions of estrogenic agents thereof |
| US6005102A (en) | 1997-10-15 | 1999-12-21 | American Home Products Corporation | Aryloxy-alkyl-dialkylamines |
| PT1025077E (pt) * | 1997-10-15 | 2007-05-31 | Wyeth Corp | Novas ariloxi-alquil-dialquilaminas |
| US6479535B1 (en) * | 1998-05-15 | 2002-11-12 | Wyeth | 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations |
| AR029538A1 (es) | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| EP1336602A1 (en) | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| AU2003245637A1 (en) | 2002-06-25 | 2004-01-06 | Wyeth | Use of thio-oxindole derivatives in treatment of hormone-related conditions |
| EP1732890A1 (en) | 2004-04-07 | 2006-12-20 | Wyeth | Crystalline polymorph of a bazedoxifene acetate |
-
2005
- 2005-04-06 EP EP05738044A patent/EP1732890A1/en not_active Withdrawn
- 2005-04-06 TW TW094110850A patent/TWI346105B/zh not_active IP Right Cessation
- 2005-04-06 CA CA002561010A patent/CA2561010A1/en not_active Abandoned
- 2005-04-06 AU AU2005233133A patent/AU2005233133A1/en not_active Withdrawn
- 2005-04-06 BR BRPI0509191-8A patent/BRPI0509191A/pt not_active IP Right Cessation
- 2005-04-06 US US11/100,983 patent/US7683051B2/en active Active
- 2005-04-06 RU RU2006132180/04A patent/RU2006132180A/ru not_active Application Discontinuation
- 2005-04-06 KR KR1020067020649A patent/KR20060135866A/ko not_active Withdrawn
- 2005-04-06 PE PE2005000386A patent/PE20060676A1/es not_active Application Discontinuation
- 2005-04-06 SG SG200902227-8A patent/SG151331A1/en unknown
- 2005-04-06 AR ARP050101367A patent/AR048527A1/es unknown
- 2005-04-06 WO PCT/US2005/011724 patent/WO2005100316A1/en not_active Ceased
- 2005-04-06 JP JP2007507487A patent/JP2007532560A/ja not_active Abandoned
- 2005-04-06 PA PA20058629101A patent/PA8629101A1/es unknown
-
2006
- 2006-09-12 CR CR8615A patent/CR8615A/es not_active Application Discontinuation
- 2006-09-21 IL IL178236A patent/IL178236A0/en unknown
- 2006-10-06 EC EC2006006911A patent/ECSP066911A/es unknown
- 2006-11-02 NO NO20065052A patent/NO20065052L/no not_active Application Discontinuation
-
2008
- 2008-06-30 JP JP2008171135A patent/JP2009035535A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| US7683051B2 (en) | 2010-03-23 |
| JP2009035535A (ja) | 2009-02-19 |
| CA2561010A1 (en) | 2005-10-27 |
| IL178236A0 (en) | 2006-12-31 |
| TW200606149A (en) | 2006-02-16 |
| JP2007532560A (ja) | 2007-11-15 |
| PA8629101A1 (es) | 2005-11-25 |
| US20050227965A1 (en) | 2005-10-13 |
| RU2006132180A (ru) | 2008-05-20 |
| EP1732890A1 (en) | 2006-12-20 |
| NO20065052L (no) | 2006-11-06 |
| PE20060676A1 (es) | 2006-07-24 |
| AU2005233133A1 (en) | 2005-10-27 |
| AR048527A1 (es) | 2006-05-03 |
| WO2005100316A1 (en) | 2005-10-27 |
| CR8615A (es) | 2007-06-06 |
| ECSP066911A (es) | 2006-12-20 |
| SG151331A1 (en) | 2009-04-30 |
| KR20060135866A (ko) | 2006-12-29 |
| TWI346105B (en) | 2011-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0509191A (pt) | polimorfo cristalino, composição, métodos de preparar forma a polimórfica de acetato de bazedoxifeno, de tratar um mamìfero possuindo uma doença ou sìndrome associada com deficiência de estrogênio ou excesso de estrogênio, e com proliferação ou desenvolvimento anormal de tecidos endometriais, cáncer de mama em um mamìfero, e uma mulher pós-menopausal para um ou vários distúrbios vasomotores, de abaixar colesterol em um mamìfero, e de inibir perda óssea em um mamìfero, e, forma a polimorfa cristalina de acetato de bazedoxifeno | |
| BRPI0509257A (pt) | polimorfo cristalino de acetato de bazedoxifeno, composição, processo para preparar um polimorfo e para aumentar a proporção de acetato de bazedoxifeno forma b em uma composição, métodos de tratar um mamìfero, cáncer de mama e uma mulher em pós-menopausa para um ou mais distúrbios vasomotores, de abaixar colesterol e de inibir perda óssea em um mamìfero e uso de um polimorfo | |
| WO2008052005A3 (en) | Compounds and methods for treating estrogen receptor-related diseases | |
| BRPI0816064B8 (pt) | composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica | |
| ZA201000079B (en) | Organic compounds | |
| BR9905788A (pt) | Derivados de 2-(2-oxo-etilideno)-imidazolidin-4-ona e composições e métodos para a inibição do crescimento de célula anormal que compreendem os referidos derivados | |
| SG170033A1 (en) | Octahydro-pyrrolo[3,4-b] pyrrole derivatives and their use as histamine-3 receptor ligands | |
| WO2011008312A3 (en) | Indole and indoline derivatives and methods of use thereof | |
| WO2010054024A3 (en) | 1, 2 -thiazol yl derivatives as cannabinoid receptor ligands | |
| WO2007112043A3 (en) | Synthetic pentacyclic triterpenoids and derivatives of betulinic acid and betulin | |
| ECSP066730A (es) | Compuestos y procedimientos para uso | |
| NO20084927L (no) | Fosfoinositid-3-kinaseinhibitorforbindelser og farmasoytiske sammensetninger inneholdende dem | |
| NZ588711A (en) | C-17 homologated oleanolic acid derivatives for treating cancer | |
| CU20110011A7 (es) | Derivados de piridazina como inhibidores de smo | |
| WO2010071783A8 (en) | Thiazoles as cannabinoid receptor ligands | |
| WO2008008310A3 (en) | Tyrosine kinase inhibitors | |
| WO2011103175A3 (en) | Oxysterols that activate liver x receptor signaling and inhibit hedgehog signaling | |
| WO2010033543A3 (en) | Substituted benzamides as cannabinoid receptor ligands | |
| WO2010028338A3 (en) | Novel compounds as cannabinoid receptor ligands | |
| SI1896421T1 (sl) | Benzocikloheptapiridini kot inhibitorji receptorjev tirozin kinaze met | |
| WO2008130879A3 (en) | Tetrahydroindole and tetrahydroindazole derivatives | |
| BR112014027337A2 (pt) | composições orgânicas para tratar doenças relacionadas com kras | |
| MY161818A (en) | Styrenyl derivate compounds for treating ophthalmic diseases and disorders | |
| MX349550B (es) | 1,7-diazacarbazoles y metodos de uso. | |
| IL191763A0 (en) | Pyrrolo [2,3-b]pyridine derivatives as h3 receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012. |